Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119661386 | 11966138 | 6 | F | 20160104 | 20160712 | 20160127 | 20160726 | PER | US-PFIZER INC-2015356428 | PFIZER | 72.00 | YR | F | Y | 0.00000 | 20160726 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119661386 | 11966138 | 1 | PS | IBRANCE | PALBOCICLIB | 1 | Oral | 125 MG ONCE DAILY FOR 21 DAYS, FOLLOWED BY A 7-DAY REST PERIOD TO COMPLETE A 28-DAY TREATMENT CYCLE | 207103 | 125 | MG | CAPSULE | |||||||
| 119661386 | 11966138 | 2 | SS | IBRANCE | PALBOCICLIB | 1 | 100 MG ONCE DAILY CYCLIC | 207103 | 100 | MG | CAPSULE | ||||||||
| 119661386 | 11966138 | 3 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | 75 MG ONCE DAILY CYCLIC (FOR 21 DAYS, FOLLOWED BY A 7-DAY REST PERIOD TO COMPLETE A 28-DAY CYCLE) | 207103 | 75 | MG | CAPSULE | |||||||
| 119661386 | 11966138 | 4 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | 75 MG, CYCLIC (21/28 DAYS) | 207103 | 75 | MG | CAPSULE | |||||||
| 119661386 | 11966138 | 5 | SS | FEMARA | LETROZOLE | 1 | Oral | 2.5 MG, 1X/DAY | U | 0 | 2.5 | MG | TABLET | QD | |||||
| 119661386 | 11966138 | 6 | SS | FEMARA | LETROZOLE | 1 | Oral | UNK | U | 0 | TABLET | ||||||||
| 119661386 | 11966138 | 7 | C | ADVAIR DISKUS | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | AS NEEDED (250-50 MCG/DOSE BLISTER) | 0 | |||||||||||
| 119661386 | 11966138 | 8 | C | PREDNISONE. | PREDNISONE | 1 | Oral | 20 MG, AS NEEDED (DAILLY) | 0 | 20 | MG | TABLET | |||||||
| 119661386 | 11966138 | 9 | C | ALBUTEROL. | ALBUTEROL | 1 | AS NEEDED (90 MCG/ACTUATION) | 0 | |||||||||||
| 119661386 | 11966138 | 10 | C | AMITRIPTYLINE | AMITRIPTYLINE | 1 | Oral | 25 MG, AS NEEDED (DAILY) | 0 | 25 | MG | TABLET | |||||||
| 119661386 | 11966138 | 11 | C | ALBUTEROL SULFATE. | ALBUTEROL SULFATE | 1 | 5 MG/ML, AS NEEDED | 0 | |||||||||||
| 119661386 | 11966138 | 12 | C | AZITHROMYCIN ANHYDROUS. | AZITHROMYCIN ANHYDROUS | 1 | Oral | 250 MG, AS NEEDED (DAILY) | 0 | 250 | MG | TABLET | |||||||
| 119661386 | 11966138 | 13 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Oral | 1 DF, DAILY (2000 UNIT CAPSULE) | 0 | 1 | DF | CAPSULE | |||||||
| 119661386 | 11966138 | 14 | C | CALCIUM CITRATE | CALCIUM CITRATE | 1 | Oral | 1000 MG, DAILY | 0 | 1000 | MG | TABLET | |||||||
| 119661386 | 11966138 | 15 | C | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | 20 MG, DAILY | 0 | 20 | MG | CAPSULE | |||||||
| 119661386 | 11966138 | 16 | C | DECADRON | DEXAMETHASONE | 1 | Oral | 12 MG, (ONCE) | 0 | 12 | MG | ||||||||
| 119661386 | 11966138 | 17 | C | ZOFRAN | ONDANSETRON HYDROCHLORIDE | 1 | Oral | 16 MG, (ONCE) | 0 | 16 | MG | TABLET | |||||||
| 119661386 | 11966138 | 18 | C | ATIVAN | LORAZEPAM | 1 | Oral | 0.5 MG, (ONCE) | 0 | .5 | MG | ||||||||
| 119661386 | 11966138 | 19 | C | TRIAMCINOLONE ACETONIDE. | TRIAMCINOLONE ACETONIDE | 1 | Topical | UNK, 2X/DAY (0.1 % CREAM 1 APPLICATION) | 0 | CREAM | BID | ||||||||
| 119661386 | 11966138 | 20 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 1060 MG, (ONCE) | 0 | 1060 | MG | ||||||||
| 119661386 | 11966138 | 21 | C | ADRIAMYCIN | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 100 MG, (ONCE) | 0 | 100 | MG | ||||||||
| 119661386 | 11966138 | 22 | C | EMEND | APREPITANT | 1 | Intravenous (not otherwise specified) | 150 MG, (ONCE) | 0 | 150 | MG | ||||||||
| 119661386 | 11966138 | 23 | C | NORMAL SALINE | SODIUM CHLORIDE | 1 | Intravenous (not otherwise specified) | 250 ML, (ONCE) | 0 | 250 | ML | ||||||||
| 119661386 | 11966138 | 24 | C | ZOMETA | ZOLEDRONIC ACID | 1 | Intravenous (not otherwise specified) | 4 MG, (ONCE) | 0 | 4 | MG | ||||||||
| 119661386 | 11966138 | 25 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
| 119661386 | 11966138 | 26 | C | LETROZOLE. | LETROZOLE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 119661386 | 11966138 | 1 | Breast cancer metastatic |
| 119661386 | 11966138 | 5 | Breast cancer metastatic |
| 119661386 | 11966138 | 7 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 119661386 | 11966138 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 119661386 | 11966138 | Arthralgia | |
| 119661386 | 11966138 | Bone pain | |
| 119661386 | 11966138 | Fatigue | |
| 119661386 | 11966138 | Neutropenia | |
| 119661386 | 11966138 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 119661386 | 11966138 | 1 | 20151111 | 0 | ||
| 119661386 | 11966138 | 3 | 20160511 | 0 | ||
| 119661386 | 11966138 | 4 | 20151111 | 0 | ||
| 119661386 | 11966138 | 5 | 20150915 | 0 | ||
| 119661386 | 11966138 | 6 | 201510 | 0 | ||
| 119661386 | 11966138 | 16 | 20150915 | 0 | ||
| 119661386 | 11966138 | 17 | 20150915 | 0 | ||
| 119661386 | 11966138 | 18 | 20150915 | 0 | ||
| 119661386 | 11966138 | 19 | 20150915 | 0 | ||
| 119661386 | 11966138 | 20 | 20150915 | 0 | ||
| 119661386 | 11966138 | 21 | 20150915 | 0 | ||
| 119661386 | 11966138 | 22 | 20150915 | 0 | ||
| 119661386 | 11966138 | 23 | 20150915 | 0 | ||
| 119661386 | 11966138 | 24 | 20150915 | 0 |